Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
130.38
+2.81 (+2.20%)
Official Closing Price
Updated: 7:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
February 26, 2024
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Via
InvestorPlace
Behind the Scenes of Merck & Co's Latest Options Trends
February 26, 2024
Via
Benzinga
What the Options Market Tells Us About Merck & Co
February 15, 2024
Via
Benzinga
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
February 14, 2024
Via
Benzinga
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Monday Morning
February 05, 2024
Via
Investor Brand Network
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
February 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2 Monster Stocks to Buy Without Any Hesitation
February 22, 2024
Investors can sleep easy at night with these stocks in their portfolios.
Via
The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
February 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
February 16, 2024
Via
Benzinga
Topics
Economy
Exposures
Economy
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
February 15, 2024
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.
Via
InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Drivers And Stock Pickers
February 13, 2024
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.
Via
Talk Markets
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
From
FN Media Group LLC
Via
GlobeNewswire
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
February 12, 2024
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
Via
Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
February 08, 2024
Investors are still excited about obesity treatments and weight-management drugs.
Via
The Motley Fool
Are these frigid Dow stocks in for a longer winter?
February 08, 2024
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
3 companies that more than doubled analyst EPS estimates
February 06, 2024
Earning season is well underway, and the separation between the winners and losers continues to grow. Of the companies that have beat
Via
MarketBeat
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
February 05, 2024
"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024."
Via
Benzinga
Merck Animal Health to Acquire Elanco’s Aqua Business
February 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.